Policy Focus On Drug Cost-Effectiveness Studies Could Take Heat Off Devices
This article was originally published in The Gray Sheet
Executive Summary
Medical devices may enjoy a temporary reprieve from policymakers' increasing calls for rigorous cost-effectiveness analyses, with the current spotlight directed on pharmaceuticals
You may also be interested in...
Carotid Artery Disease Screening Should Make AHRQ Research List – Guidant
Guidant is requesting the Agency for Healthcare Research & Quality to assign the study of female cardiovascular care quality to a list of CMS research priorities to be generated under the Medicare Modernization Act
AdvaMed Issues National Coverage Evidentiary Standards Policy Statement
AdvaMed plans to disseminate its 1national coverage evidence standards policy statement to Capitol Hill staffers and CMS officials
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.